USA flag logo/image

An Official Website of the United States Government

Rapid Identification of Pathogenic Bacteria and Sepsis Diagnosis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R44AI094781
Solicitation Year:
2013
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
ISENSE, LLC
500 AUSTRALIAN AVE S, STE 120 WEST PALM BEACH, FL 33401-6223
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2013
Title: Rapid Identification of Pathogenic Bacteria and Sepsis Diagnosis
Agency: HHS
Contract: 2R44AI094781-02
Award Amount: $1,956,109.00
 

Abstract:

DESCRIPTION (provided by applicant): Sepsis is the tenth-leading cause of death in the United States and the second-leading cause of death in the intensive care unit (ICU). Sepsis kills over 215,000 Americans each year - more than breast cancer, lung cancer, and prostate cancer combined. Rapid identification and determination of antibiotic susceptibility is critical fo effective treatment of infected patients. Phase I successfully demonstrated the iSense system's ability to discriminate bacterial species and strain 4-fold faster than legacy methods identify species alone. In Phase I iSense also successfully demonstrated the ability to determine strain-specific susceptibility to antibiotic therapy more than 1 day faster than conventional practice. Phase II aims address application to clinical human specimens along with development of instruments and media appropriate for commercial use. The ultimate goal of this research is to develop and commercially deploy an automated blood culture system that can diagnosesepsis, identify the species and strain of the infecting organism, and determine antibiotic susceptibility all in less than 24 hours from the lab's receipt of primary specimen. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Sepsis kills over 215,000 Americans each year - more than breast cancer, lung cancer, and prostate cancer combined. Rapid identification and determination of antibiotic susceptibility is critical for effective treatment of infected patients The ultimate goal of this researchis to develop and an automated system that returns results in less than 24 hours, 3 times faster than current practices.

Principal Investigator:

Ray A. Martino
650-938-6200
rmartino@isensesystems.com

Business Contact:

Ray Martino
408-390-1900
rmartino@isensesystems.com
Small Business Information at Submission:

ISENSE, LLC
500 AUSTRALIAN AVE S, STE 120 WEST PALM BEACH, FL 33401-6223

EIN/Tax ID: 126042099
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No